ICER Enhanced Patient Engagement Program Will Be Led By Former Biopharma Exec
Yvette Venable has more than 20 years’ experience in patient advocacy, heath policy and biopharma communications.
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.
Eisai/Biogen’s promising Phase III data fueling the companies’ hopes that Medicare will relax coverage restrictions for their Alzheimer’s treatment candidate. If the sponsors fail to change the NCD, lecanemab will need to rely on a registry for reimbursement after full approval.